BRIEF-GSK and Theravance to file Relvar Ellipta for COPD in Japan
September 24, 2015 at 03:15 AM EDT
* This decision follows results from an additional global phase 3 efficacy and safety study.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.